Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance

Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named to Seramount's (formerly Working Mother media) 2022 Inclusion Index.

Horizon Therapeutics plc Named to the Seramount Inclusion Index

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Oct. 26-28 in Amsterdam.

New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on real-world TEPEZZA (teprotumumab-trbw) use at the American Thyroid Association (ATA) 2022.

New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) to be presented at the American Thyroid Association (ATA) 2022.

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) will be presented at ECTRIMS 2022.

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to Newsweek's 2022 Top 100 Most Loved Workplaces® list for prioritizing respect, caring and appreciation for employees. The Newsweek list is the result of a collaboration with the Best Practice Institute (BPI), a leadership development and benchmark research company. The full list will be featured in the magazine's Oct. 14 print edition and is currently available online. “It is especially mea

Horizon Therapeutics plc Named to Newsweek's 2022 Top 100 Most Loved Workplaces

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequat

Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on the key drivers of Thyroid Eye Disease (TED) at the American Academy of Ophthalmology (AAO) 2022.

New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.

Horizon (HZNP) Completes Enrollment in Phase IV TED Study

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inflammatory signs and symptoms that are often associated with TED.1 Topline results are expected in the second quarter of 2023. TED is a serious,

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts and math (STEAM) careers and historically Black colleges and universities (HBCUs) through its Horizon Scholars program, which now includes a student at Meharry Medical College. The Horizon Scholars program provides scholarships to cover student debt burden while simultaneously offering professional mentorship, peer networking and internships

Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year's Horizon Prize: Patient-Driven Data Platform for Rare Disease by EB Research Partnership. The EB Research Partnership will receive $150,000 in funding to continue improving the quality of life of people who have been diagnosed with EB, a family of life-threatening rare genetic disorders that affect

Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations on its marketed and pipeline medicines, with a focus on continued efforts to advance the understanding and care of uncontrolled gout, during the American College of Rheumatology Convergence 2022 to be hosted in Philadelphia and online, Nov. 10-14, 2022. Key results from the MIRROR randomized controlled trial will be presented as part of the American College of Rheumatology C

Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of data from the MIRROR randomized controlled clinical trial of KRYSTEXXA (pegloticase) injection with methotrexate, a commonly used immunomodulator, in Arthritis & Rheumatology [https://doi.org/10.1002/art.42335]. “The publication of this data coupled with the recently expanded labeling provides clinicians the opportunity to evolve how we care for patients with uncontrolled gout,” said Suneet G

Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with World Sight Day organizers IAPB to challenge five million people globally to pledge to have their vision checked before World Sight Day on Oct. 13. This year's theme is #LoveYourEyes and calls on individuals to prioritize their eye health, while raising awareness about the challenges faced by the one billion people worldwide who cannot access or afford eye care services. “We are proud to support World Sight Day

Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity as defined by the European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥ 5. At Week 24, patients treated with dazodalibep achieved a 6.3-point reduction in their ESSDAI score and pa

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren's Syndrome Meets Primary Endpoint

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Announces $500 Million Share Repurchase Program

Horizon Therapeutics plc Announces $500 Million Share Repurchase Program

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category. This is the sixth consecutive year Horizon has been named to the list and the company's third time ranking No. 1. "It's a tremendous honor to be named the No. 1 Best Workplace in Biopharma for the second consecutive year,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “At Horizo

Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?

Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth with multiple catalysts ahead.

Why Horizon Therapeutics Is One Of The Best Investments In Biotech Today

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the PEOPLE 100 Companies That Care list by PEOPLE and Great Place to Work. The list highlights the top U.S. companies that have succeeded in business while also demonstrating outstanding respect, care and concern for their employees, their communities and the environment. The list will also be featured in the Sept. 12 print issue of PEOPLE, which will be available on newsstands nationwide

News for Horizon Pharma Stock (HZNP)